# Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

> **NCT04066244** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** BLZ945

## Key facts

- **NCT ID:** NCT04066244
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-30
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study terminated after assessment of potential benefit-risk from available data
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066244, "Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04066244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*